Abstract Number: 1618 • ACR Convergence 2024
Co-occurrence of Giant Cell Arteritis and Polymyalgia Rheumatica: Insights from a Retrospective Analysis
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related conditions that often co-occur.1 Approximately half of all patients with GCA experience PMR…Abstract Number: 0741 • ACR Convergence 2024
Serum Markers of Disease Activity in Polymyalgia Rheumatica
Background/Purpose: A significant unmet need in Polymyalgia Rheumatica (PMR) is the lack of a disease specific serum biomarker for diagnosis, and monitoring of disease activity.…Abstract Number: 1619 • ACR Convergence 2024
Challenges in Managing Polymyalgia Rheumatica and Giant Cell Arteritis: Steroid Dependence and Preventive Care
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are systemic inflammatory disorders treated with prolonged corticosteroid therapy. Prolonged use of corticosteroids is a significant…Abstract Number: 0743 • ACR Convergence 2024
Higher Baseline FDG Musculoskeletal Uptake at PET/CT Is Associated with a Higher Remission Rate in Polymyalgia Rheumatica: A Retrospective 3-year Observational Study
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory diseases characterized by increased musculoskeletal and vascular uptakes of 18-Fluorodeoxyglucose (18F-FDG) at positron…Abstract Number: 1622 • ACR Convergence 2024
18F-FDG PET/CT in LVV During Active and Inactive Disease Phases Is Associated with the Metabolic Profile, but Not with Macrophage-related Cytokines: Results of an Integrated Analysis
Background/Purpose: Giant cell arteritis (GCA) may affect temporal arteries (cranial-GCA) or may present as a systemic disease extended to the large vessels [Large Vessel Vasculitis…Abstract Number: 0747 • ACR Convergence 2024
Clofutriben to Improve the Benefit-Risk Profile of Prednisolone in Patients with Polymyalgia Rheumatica
Background/Purpose: 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) differentially regulates intracellular glucocorticoid levels in the immune system and glucocorticoid toxicity target organs. Clofutriben is a potent HSD-1…Abstract Number: 1629 • ACR Convergence 2024
Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vascular Ultrasound Phenotype Than Giant Cell Arteritis
Background/Purpose: Subclinical GCA in PMR has been estimated to affect 1 in 5 patients as assessed by vascular ultrasound [1, 2]. This study compared the ultrasound…Abstract Number: 0748 • ACR Convergence 2024
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Background/Purpose: Treatment of polymyalgia rheumatica (PMR) is hindered by lack of glucocorticoid (GC)-sparing therapies with proven efficacy. A retrospective study showed a higher proportion of…Abstract Number: 1637 • ACR Convergence 2024
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Background/Purpose: The dysregulation of the immune system inherent in inflammatory diseases may contribute to the development of neoplasms. However, the relationship between the giant cell…Abstract Number: 0755 • ACR Convergence 2024
Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR), a common inflammatory rheumatic condition in people aged ≥50 years, is primarily treated with glucocorticoids (GC). Extended GC therapy can increase…Abstract Number: 1697 • ACR Convergence 2024
Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica
Background/Purpose: The most effective treatment for Polymyalgia rheumatica (PMR) are glucocorticoids (GC), but these are associated with toxicity. Three randomized controlled trials (RCTs) suggest methotrexate…Abstract Number: 0756 • ACR Convergence 2024
Effectiveness and Safety of Tocilizumab in the Treatment of Polymyalgia Rheumatica: A Meta-Analysis
Background/Purpose: Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) are different manifestations of the same disease process. GCA is a vasculitis that affects large and…Abstract Number: 1698 • ACR Convergence 2024
Assessment of the Remission Maintenance After Tocilizumab Withdrawal in Polymyalgia Rheumatica Patients Receiving a 6-month Treatment
Background/Purpose: The SEMAPHORE trial1 was a randomized controlled prospective study to assess the safety and efficacy (success defined by PMR-AS≤10 and GC≤5mg or GC decrease…Abstract Number: 0762 • ACR Convergence 2024
Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications
Background/Purpose: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischemic complications (IC) in giant cell arteritis (GCA).Methods: Retrospective…Abstract Number: 1700 • ACR Convergence 2024
Comparative Effectiveness of Sarilumab vs. Methotrexate as a Glucocorticoid-Sparing Agent in Patients with Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that typically affects older individuals for whom long term glucocorticoid (GC) use may be undesirable. Moreover, the…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »